US equities
|
TSLA
$393.22
▲+5.64%
MU
$883.83
▲+0.72%
SPCX
$145.42
▼-1.40%
META
$631.98
▼-1.66%
NVDA
$213.94
▲+1.41%
AAPL
$343.42
▼-1.24%
SNDK
$1,237.72
▼-0.03%
INTC
$86.64
▼-0.36%
TSLA
$393.22
▲+5.64%
MU
$883.83
▲+0.72%
SPCX
$145.42
▼-1.40%
META
$631.98
▼-1.66%
NVDA
$213.94
▲+1.41%
AAPL
$343.42
▼-1.24%
SNDK
$1,237.72
▼-0.03%
INTC
$86.64
▼-0.36%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Clearmind Medicine Inc. - Common Shares
(NQ:
CMND
)
5.920
+0.050 (+0.85%)
Delayed Quote
Updated: 9:33 AM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Clearmind Medicine Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
April 17, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
April 16, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
April 10, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
April 08, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
April 01, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
March 21, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
March 19, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
March 18, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Bulls Turn to Pennies STSS, ADTX, CSDX, SPRC, CBDW, YGTFF During Market Uncertainty – Small-Cap Stocks Poised for Big Moves
March 10, 2025
Via
AB Newswire
Topics
Intellectual Property
SciSparc Shares Are Soaring Monday: What's Going On?
↗
March 10, 2025
SciSparc Ltd (NASDAQ:SPRC) shares are ripping higher Monday after the company announced that its collaboration with Clearmind Medicine Inc (NASDAQ:CMND) led to a patent application for psychedelic...
Via
Benzinga
Topics
Intellectual Property
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
March 10, 2025
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
March 10, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
February 04, 2025
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
February 04, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Shareholders Meeting Results
January 07, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?
↗
January 06, 2025
SciSparc teams up with Clearmind Medicine on innovative therapies for binge behaviors and secures FDA approval for a Tourette Syndrome Phase 2b trial.
Via
Benzinga
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
January 06, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
January 06, 2025
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
January 02, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
December 26, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Why Is Penny Stock Clearmind Gaining Today?
↗
December 24, 2024
Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder.
Via
Benzinga
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
December 24, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
December 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
↗
October 11, 2024
Via
Benzinga
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
October 10, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
↗
September 17, 2024
Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy.
Via
Benzinga
Topics
Intellectual Property
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
September 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
September 12, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
